159 related articles for article (PubMed ID: 21651982)
1. Chemically modified tetracycline-3 (CMT-3): a novel inhibitor of the serine proteinase, elastase.
Gu Y; Lee HM; Simon SR; Golub LM
Pharmacol Res; 2011 Dec; 64(6):595-601. PubMed ID: 21651982
[TBL] [Abstract][Full Text] [Related]
2. A combination of a chemically modified doxycycline and a bisphosphonate synergistically inhibits endotoxin-induced periodontal breakdown in rats.
Llavaneras A; Ramamurthy NS; Heikkilä P; Teronen O; Salo T; Rifkin BR; Ryan ME; Golub LM; Sorsa T
J Periodontol; 2001 Aug; 72(8):1069-77. PubMed ID: 11525440
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of proteolytic, serpinolytic, and progelatinase-b activation activities of periodontopathogens by doxycycline and the non-antimicrobial chemically modified tetracycline derivatives.
Grenier D; Plamondon P; Sorsa T; Lee HM; McNamara T; Ramamurthy NS; Golub LM; Teronen O; Mayrand D
J Periodontol; 2002 Jan; 73(1):79-85. PubMed ID: 11846203
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines.
Ramamurthy NS; Rifkin BR; Greenwald RA; Xu JW; Liu Y; Turner G; Golub LM; Vernillo AT
J Periodontol; 2002 Jul; 73(7):726-34. PubMed ID: 12146531
[TBL] [Abstract][Full Text] [Related]
5. Blocking periodontal disease progression by inhibiting tissue-destructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs.
Rifkin BR; Vernillo AT; Golub LM
J Periodontol; 1993 Aug; 64(8 Suppl):819-27. PubMed ID: 8410621
[TBL] [Abstract][Full Text] [Related]
6. Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug.
Lee HM; Ciancio SG; Tüter G; Ryan ME; Komaroff E; Golub LM
J Periodontol; 2004 Mar; 75(3):453-63. PubMed ID: 15088884
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model.
Lokeshwar BL; Selzer MG; Zhu BQ; Block NL; Golub LM
Int J Cancer; 2002 Mar; 98(2):297-309. PubMed ID: 11857423
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of breast cancer cell extracellular matrix degradative activity by chemically modified tetracyclines.
Gu Y; Lee HM; Golub LM; Sorsa T; Konttinen YT; Simon SR
Ann Med; 2005; 37(6):450-60. PubMed ID: 16203617
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic suppression of experimental abdominal aortic aneurysms: acomparison of doxycycline and four chemically modified tetracyclines.
Curci JA; Petrinec D; Liao S; Golub LM; Thompson RW
J Vasc Surg; 1998 Dec; 28(6):1082-93. PubMed ID: 9845660
[TBL] [Abstract][Full Text] [Related]
10. Chemically modified tetracyclines act through multiple mechanisms directly on osteoclast precursors.
Holmes SG; Still K; Buttle DJ; Bishop NJ; Grabowski PS
Bone; 2004 Aug; 35(2):471-8. PubMed ID: 15268899
[TBL] [Abstract][Full Text] [Related]
11. The nonantimicrobial properties of tetracycline for the treatment of periodontal disease.
Vernillo AT; Ramamurthy NS; Golub LM; Rifkin BR
Curr Opin Periodontol; 1994; ():111-8. PubMed ID: 8032451
[TBL] [Abstract][Full Text] [Related]
12. Functional sites of chemically modified tetracyclines: inhibition of the oxidative activation of human neutrophil and chicken osteoclast pro-matrix metalloproteinases.
Sorsa T; Ramamurthy NS; Vernillo AT; Zhang X; Konttinen YT; Rifkin BR; Golub LM
J Rheumatol; 1998 May; 25(5):975-82. PubMed ID: 9598901
[TBL] [Abstract][Full Text] [Related]
13. Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity.
Ryan ME; Usman A; Ramamurthy NS; Golub LM; Greenwald RA
Curr Med Chem; 2001 Feb; 8(3):305-16. PubMed ID: 11172685
[TBL] [Abstract][Full Text] [Related]
14. Blocking Periodontal Disease Progression by Inhibiting Tissue-Destructive Enzymes: A Potential Therapeutic Role for Tetracyclines and Their Chemically-Modified Analogs.
Rifkin BR; Vernillo AT; Golub LM
J Periodontol; 1993 Aug; 64 Suppl 8S():819-827. PubMed ID: 29539753
[TBL] [Abstract][Full Text] [Related]
15. Role of Chemically Modified Tetracyclines in the Management of Periodontal Diseases: A Review.
Ghangurde AA; Ganji KK; Bhongade ML; Sehdev B
Drug Res (Stuttg); 2017 May; 67(5):258-265. PubMed ID: 28268238
[TBL] [Abstract][Full Text] [Related]
16. In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: relationship to bone and cartilage degradation.
Greenwald RA; Golub LM; Ramamurthy NS; Chowdhury M; Moak SA; Sorsa T
Bone; 1998 Jan; 22(1):33-8. PubMed ID: 9437511
[TBL] [Abstract][Full Text] [Related]
17. Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers.
Lokeshwar BL
Pharmacol Res; 2011 Feb; 63(2):146-50. PubMed ID: 21093590
[TBL] [Abstract][Full Text] [Related]
18. Introduction and background.
Golub LM
Pharmacol Res; 2011 Feb; 63(2):99-101. PubMed ID: 20937387
[TBL] [Abstract][Full Text] [Related]
19. Structural and dynamics analysis of matrix metalloproteinases MMP-2 complexed with chemically modified tetracyclines (CMTs).
Marcial BL; Sousa SF; Santos HF; Ramos MJ
J Biomol Struct Dyn; 2014 Dec; 32(12):1907-18. PubMed ID: 24125013
[TBL] [Abstract][Full Text] [Related]
20. Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular-matrix bound basic fibroblast growth factor.
Thompson K; Rabinovitch M
J Cell Physiol; 1996 Mar; 166(3):495-505. PubMed ID: 8600153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
